RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Combination DCV/SOF is Effective in Achieving Sustained Response in Patients with HCV GT-3
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 12
OP 13
DO 10.1177/155989771448006
UL http://mdc.sagepub.com/content/14/48/12.abstract
AB Hepatitis C virus genotype (GT)-3 is common worldwide and is accompanied by a significant disease burden. Among patients with cirrhosis, it is associated with increased risk of fibrosis progression, steatosis, and hepatocellular carcinoma. The Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV [ALLY-3; NCT02032901] trial evaluated the efficacy and safety of daclatasvir plus sofosbuvir in patients chronically infected with GT-3.